LJAC
ALXN

L.J. Altfest & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

L.J. Altfest & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,211
Closed -$345K – 305
2020
Q4 		$345K Sell
2,211
-8
-0.4% -$1.03K 0.08% 181
2020
Q3 		$254K Sell
2,219
-7
-0.3% -$755 0.07% 186
2020
Q2 		$250K Buy
+2,226
New +$236K 0.07% 185

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

L.J. Altfest & Co's ALXN Position: Q1 2021 in Review

L.J. Altfest & Co sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 2,211 shares — an estimated $345K sold.

L.J. Altfest & Co first reported a position in ALXN in Q2 2020 and held it in 3 quarters. The position peaked at $345K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • L.J. Altfest & Co reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • L.J. Altfest & Co sold 2,211 Alexion Pharmaceuticals shares in Q1 2021, an estimated $345K.
  • L.J. Altfest & Co first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • L.J. Altfest & Co's Alexion Pharmaceuticals position peaked at $345K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on L.J. Altfest & Co's 13F filing for Q1 2021, filed 7 May 2021.